ABIVAX Société Anonyme (NASDAQ: ABVX) is highlighted as one of the best emerging technology stocks to invest in. Guggenheim analyst Yatin Suneja raised the firm’s price target on ABIVAX to $175 from $150 with a Buy rating due to the optimistic outlook for obefazimod in the 44-week maintenance readout.

In financial news, ABIVAX reported Q3 2025 results with $2.40 million in revenue, surpassing estimates by $1.06 million. However, there was a loss per share of $1.68, and the net loss for nine months widened to €254.1 million. The company’s financial focus remains on obefazimod, a first-in-class oral miR-124 enhancer.

Research and development expenses for ABIVAX rose to €133.4 million, driven by the ABTECT Phase 3 program in ulcerative colitis/UC and the ENHANCE-CD Phase 2b trial in Crohn’s disease. The company is gearing up for major milestones in 2026, with topline results from the ABTECT Maintenance Trial expected in the second quarter and plans for an NDA submission to the FDA in the second half of that year.

ABIVAX Société Anonyme (NASDAQ: ABVX) is a clinical-stage biotechnology company specializing in therapeutics that stabilize the immune response in patients with chronic inflammatory diseases. Investors are advised to consider other AI stocks with potentially greater upside and less downside risk.

For more investment insights, check out articles on “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. This article does not contain any promotional disclosure and was originally published by Insider Monkey.

Read more at Yahoo Finance: Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout